12 results
-The primary objective of this study is to investigate the pharmacokinetics of olaparib after a single oral dose of 300 mg to patients with advanced solid tumours and mild or moderate renal impairment compared to those with normal renal function.-…
* The primary objective of this study is to investigate the effect of rifampicin on the pharmacokinetics (PK) of olaparib following oral dosing of the tablet formulation in patients with advanced solid tumours.* The secondary objectives are to…
The primary objective of this study is to investigate the effect of food on the pharmacokinetics(PK) of olaparib following oral dosing of the tablet formulation in patients with advancedsolid tumours.The secondary objectives are to investigate the…
PrimaryTo assess the safety and tolerability of olaparib when given in addition to abiraterone and torecommend, by assessment of dose-limiting toxicities and other safety and tolerability data, adose of olaparib for further study when given in…
The primary objective of this study is to investigate the effect of itraconazole on thepharmacokinetics (PK) of olaparib following oral dosing of the tablet formulation inpatients with advanced solid tumours.The secondary objectives are: to…
The primary objective of this study is to investigate the effect of food on the pharmacokinetics (PK) of olaparib following oral dosing of the capsule formulation in patients with advanced solid tumours.The secondary objective is to further…
The purpose of this clinical investigation is to verify the efficacy and safety of the CVRx Neo Baroreflex Activation Therapy System in subjects who qualify for the implantation for a Baroreflex Activation Therapy System.
The purpose of this clinical inestigation is to verify the efficacy and safety of the CVRx Neo baroreflex Activation Therapy System in subjects with heartfailure.
-The primary objective of this study is to investigate the pharmacokinetics (PK) of olaparib after a single oral dose of 300 mg to patients with advanced solid tumours and mild or moderate hepatic impairment compared to those with normal hepatic…
The primary objective of the study is to determine feasibility of CEA assessments at home using (automated) capillary sampling. Home based (automated) capillary sampling will be considered feasible if a success rate of 85% or greater has been…
The primary objective of this study is to determine the immune-activating capacity of treatment with pembrolizumab and carboplatin/paclitaxel in the neo-adjuvant setting of primary stage IV ovarian cancer as measured by the alteration in magnitude…
To assess the effect of MEDI4736 in combination with olaparib±bevacizumab in patients with selected advanced solid tumors.To assess the safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) in patients with selected…